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Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive and frequently lethal cystic
lung disease that almost exclusively affects women and has no proven therapies. An improved
understanding of the pathogenesis has identified promising molecular targets for clinical trials.
Although barriers, modifiers, and benefits for clinical trial participation in common diseases such
as cancer have been studied, we are unaware of such evaluations concerning rare diseases.
Methods: We performed a survey of a population-based registry of 780 LAM subjects in North
America to identify predictors of trial participation. Logistic regression analysis evaluated the
association of demographic and clinical features with trial participation.
Results: 41 of 263 (16%) LAM patient respondents in North America had participated in a clinical
trial. Age, disease duration, lack of any college education, use of oxygen therapy, and presen-
tation without chest pain were associated with trial participation in unadjusted analyses. Multi-
variate analyses indicate that patient age was the strongest independent predictor for trial
participation (ORZ 2.07, pZ 0.004 per decade greater of patient age). Common reasons re-
ported against trial participation included not meeting enrollment criteria (44%), drug toxicity
(25%), and stable disease (20%). The most frequent reason reported for trial participation was
to help future patients (85%).
Conclusions: Study entry criteria, drug toxicity, and stability of disease are barriers to trial
enrollment among subjects with LAM. Older LAM patients and those with more advanced disease
are more likely to have participated in clinical trials. Altruism is commonly a motivating factor.
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trials that are enrolling tuberous sclerosis and LAM patientsFor rare, chronic, and terminal illnesses that have no known
cure, clinical trials offer the best hope of discovering an
effective treatment. However, trials may not yield helpful
results if an insufficient number of patients participate.
Difficulty in recruitment to a trial may limit the statistical
power of the study to detect a possible treatment effect.
Furthermore, the external validity of the trial is limited if
the study sample is not representative of the population at
large in which the treatment might be used. Previous
literature has established the barriers to participation in
clinical trials in specific disease categories (e.g. coronary
artery disease patients) and underrepresented demo-
graphic groups (e.g. women and African Americans). For
women in general, the major perceived barriers to partic-
ipation in clinical trials include increased burden on health
and time, inconvenience of appointments, and increased
risk of harm.1e3 Barriers and benefits involved in partici-
pating in randomized controlled trials of patients with
cancer (representative of chronic, terminal diseases of
large population size) have also been well studied and the
major barriers include fear of trials, competing clinical
trials, and information overload.4 In women with gyneco-
logic malignancies, distrust of trials and time burdens have
been cited as causes for unwillingness to participate.1,3,5 To
our knowledge, such barriers have not been evaluated in
the setting of rare diseases.
Lymphangioleiomyomatosis (LAM) is a rare, progressive,
frequently lethal cystic lung disease that almost exclusively
affects women with an estimated prevalence of 2 patients
per million people.6,7 It occurs in up to 40% of women with
the tuberous sclerosis complex, and can also present in
a sporadic form that involves the lung, lymphatics, and
kidney (in the form of angiomyolipomas (AMLs)6,7), but
without systemic genetic disease. Among all LAM patients,
mortality at 10 years has been estimated to be approxi-
mately 10e20% from the onset of symptoms8,9 and 30% at 10
years from the time of lung biopsy.10 The current treat-
ments for LAM are primarily based on the antagonism of
estrogen action and remain empiric and unproven.11
Improved understanding of the molecular pathogenesis of
the disease has identified several promising molecular
targets for clinical trials. In particular, dysregulation in
mTOR signaling pathway due to loss of the growth regula-
tory protein, tuberin, has been shown to result in abnormal
cell proliferation in LAM. An FDA approved mTOR inhibitor
called sirolimus has been reported to restore normal cell
growth in the laboratory and to cause tumor regression in
animal models of tuberin deficiency. The Cincinnati
Angiomyolipoma Sirolimus Trial (registration identifier,
NCT00457808) was a proof-of-principle trial involving 20
patients with angiomyolipomas, including 11 with LAM,12
which showed an improvement in lung function after 1 year
of treatment. A large, 3-year, randomized controlled trial
called the Multicenter International LAM Efficacy of Siroli-
mus (MILES) trial (NCT00414648) opened in 2006. Octreo-
tide, which slows the production of chyle through reduction
in splanchnic blood flow, has been tested in LAM patients in
a clinical trial at the National Heart, Lung, and Blood
Institute (NCT00005906). There are also three open AMLat the current time, all based on tumor volume endpoints
(NCT NCT00790400, NCT00457964, NCT00792766).
The particular challenges of trial recruitment in rare
diseases may differ from those barriers studied previously
in other groups. We are unaware of any published studies
evaluating predictors of participation, barriers, and
perceived benefits of clinical trials in rare disease pop-
ulations. Therefore, we studied persons affected with LAM
in order to determine the demographic and clinical factors
associated with clinical trial participation and to investi-
gate the reasons for and against the decision to enroll in
a clinical trial.
Methods
We developed a questionnaire to document respondents’
demographic information, clinical data, and reasons for
choosing to enroll or not to enroll in clinical trials. We asked
subjects whether they had participated in at least one
clinical trial and allowed the subjects to specify the
particular trial/s in free text. Themes relating to barriers,
motivating factors and modifiers to participation obtained
from published literature were used to generate questions.
A focus group using semi-structured interviewing tech-
niques (including open-ended and free-response formats)
of LAM patients was conducted. The responses from this
session and ensuing discussion were used to generate
a semi-structured survey consisting of both multiple choice
and free-response questions that required about 15e30 min
to complete. Face and content validity were ensured by
using different questions to elicit the same information.
With the help of the LAM Foundation, a nonprofit orga-
nization founded to further patient and physician support
and education and to enhance research efforts in LAM, we
contacted LAM patients and/or family members in North
America who had previously given consent to allow disclo-
sure of their names to researchers. The questionnaire was
distributed to 780 self-identified LAM patients (all patients
and caregivers of current (nZ 621) and deceased (nZ 159)
patients for which addresses were available listed in the
Foundation’s population-based registry) requesting that
they complete either the online questionnaire or the
mailed questionnaire between July 2008 and December
2008. The questionnaire was sent both in paper form and
via email with a link to a web-based survey site (www.
surveymonkey.com). Respondents could return the ques-
tionnaire by mail, fax, or email, and they received no
incentive for participation. Each questionnaire was
assigned a random LAM identification number. Data from
completed questionnaires were entered into the web-based
survey site and were exported as a Microsoft Excel data-
base. This study was approved by the institutional review
board of the University of Cincinnati College of Medicine.
The predictor variables examined included age, educa-
tional level, income level, region of residence, disease
duration, forced expiratory volume in 1 s (FEV1) (at diag-
nosis and most recent), presentation type (i.e. pneumo-
thorax or dyspnea), employment status, insurance status,
length of diagnosis, location of care, and main provider
type (pulmonologists or other). Descriptive characteristics
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factors regarding clinical trial participation were calculated
as percentages of the total responses in each category. In
the unadjusted analysis, the main outcome of presence or
absence of trial participation utilized Fisher’s exact test/
Chi square, as appropriate, with two tailed p-values < 0.05
considered statistically significant. Variables found to be
associated at a p value of <0.05 were considered for
inclusion in the multivariate logistic regression model. The
final model was selected using backwards deletion. Anal-
yses were performed using Stata statistical software,
version 9 (College Station, Texas).
Results
Of 780 questionnaires distributed, 263 were returned and
included in the analysis. There was a very low response rate
from family members of deceased patients (1/159).
Amongst surviving members of the database, the response
rate was 262/621(42%). 41 of 263 (16%) respondents in
North America had participated in a clinical trial for LAM.
The responding population was predominantly Caucasian
and similar in age to the LAM Foundation registry overall.
Clinical trial participants were older (mean ageZ 53) than
non-participants (mean ageZ 49, p valueZ 0.001) and
tended to have longer disease duration (Table 1). Those
subjects citing altruism as a motivating factor for clinical
trial enrollment were older and had longer disease duration
than those that did not (p valueZ 0.01 and 0.002,
respectively; data not shown). The presenting symptoms
leading to diagnosis were similar between participants andTable 1 General characteristics and clinical features associate
Variables Overa
measu
Age, mean (SD) 263
Caucasian, number (%) 263
Disease duration, years (SD) 239
Established disease,a number (%) 208
No established disease,a number (%) 55
Presentation withb
Dyspnea, number (%) 263
Kidney tumor, number (%) 263
Pneumothorax, number (%) 263
Chest pain, number (%) 263
Asymptomatic, number (%) 263
Ever smoker, number (%) 256
Diagnosis by
Surgical lung biopsy, number (%) 111/2
Abdominal/lymph node biopsy, number (%) 23/26
Under the care of a pulmonologist, number (%) 211/2
Main care at an academic medical center, number (%) 126/2
Recent FEV1, mean % predicted (SD) 84
At diagnosis FEV1, mean % predicted (SD) 79
Oxygen therapy, number (%) 221
a Established diseaseZ disease duration of greater than 3 years.
b Symptoms not mutually exclusive.non-participants with the exception of chest pain, which
was more common among those not enrolled in a clinical
trial (24% vs 10%, pZ 0.04). Approximately 51% had
undergone either surgical lung biopsy or biopsy of abdom-
inal tissues or lymph nodes, but there was no difference in
tissue confirmation rates between trial participants and
non-participants. In both groups, the majority of respon-
dents were non-smokers and under the care of pulmonol-
ogists. Clinical trial participants had a slightly lower most
recent FEV1% predicted, but it did not reach statistical
significance (59% vs 65%, pZ 0.39). More clinical trial
participants were on supplemental home oxygen than non-
participants (63% vs 40%, pZ 0.009). There was no
observed association between region of residence, as
classified by the US Census Bureau, and trial participation
(data not shown). Although the majority of subjects in both
groups were college educated, there were fewer with
advanced education among the clinical trial participants
(73% vs 90%, pZ 0.009) (Table 2). In addition, clinical trial
participants were more likely to have experienced disease
related job loss (47% vs 24%, pZ 0.008). Income and
current job status did not differ between the two groups,
and almost all subjects had some health insurance.
Results of multivariate analyses indicate that patient
age was the strongest independent predictor for trial
participation (ORZ 2.07, CI 1.26e3.41, pZ 0.004 for each
decade greater in patient age) (Table 3). Oxygen use and
absence of chest pain presentation approached but did not
meet statistical significance criteria.
The most common reasons against trial participation
were not meeting enrollment criteria (44%), potential drugd with clinical trial participation.
ll number
red
Clinical trial
participants
(nZ 41)
Non-participants
(NZ 222)
p-value
53 (8) 49 (10) 0.001
36 (88) 191 (86) 1.00
11 (7) 9 (6) 0.060
38 (18) 170 (82) 0.020
3 (8) 48 (92)
28 (68) 142 (64) 0.594
7 (17) 30 (14) 0.547
14 (34) 91 (41) 0.411
4 (10) 54 (24) 0.039
2 (5) 22 (10) 0.304
16 (39) 68 (32) 0.355
63 (42%) 17 (41) 94 (42) 0.917
3 (9%) 4 (10) 19 (9) 0.803
63 (80%) 36 (88) 175 (79) 0.185
63 (48%) 19 (46) 107 (48) 0.827
59 (26) 65 (27) 0.394
72 (18) 72 (23) 0.990
24 (63) 73 (40) 0.009
Table 2 Socioeconomic factors associated with clinical trial participation.
Variables Overall number
measured
Clinical trial
participants
Non-participants p-value
Employed, number (%) 263 17 (41) 98 (44) 0.751
On Disability, number (%) 178 16 (50) 47 (32) 0.056
College educated, number (%) 263 30 (73) 199 (90) 0.009
Income, number (%) 227
Less than $30,000/year 3 (9) 25 (13) 0.775
Greater than $100,000/year 9 (28) 54 (28) 1.00
Insurance coverage, number (%) 256 41 (100) 212 (99) 0.447
Disease related job loss (%) 179 15 (47) 35 (24) 0.008
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grouped into common themes for non-participation, 46%
reported eligibility issues, 36% personal/logistical concerns,
and 45% cited perceived risks (total not equal to 100% as
responses were not mutually exclusive). Notably, aware-
ness of studies, study costs, risk of placebo assignment, and
off-label medication use were not widely cited as obstacles
to trial participation. The most frequent reasons given for
trial participation were to help future patients (85%), learn
about the disease (66%), closer monitoring (63%), and
access to therapies (61%) (Fig. 2).
Discussion
Over 7000 rare diseases, each involving fewer than 200,000
US residents, affect nearly 30 million people in the United
States.13 Clinical investigators in rare disease research
regularly face challenges specific to the study of uncommon
disorders, such as the recruitment of sufficient numbers of
study subjects for adequately powered clinical trials.
Strategies that have been used to attempt to surmount
these challenges include the creation of multi-institutional
and international collaborations, adoption of specialized
study designs, biostatistical techniques developed to
maximize data from small numbers of subjects, and part-
nerships with patient advocacy organizations.13 However,
we are unaware of any published study that systematically
evaluates the predictors, barriers and motivating factors
for clinical trial enrollment among patients with rare lung
diseases such as LAM. We found that the predictors of trial
participation in this rare disease differ from prior studies of
cancer patients or underrepresented minority groups in
general such as women.Table 3 Multivariate logistic regression model for factors
associated with clinical trial participation.
Predictor variables Odds
ratio
95%CI P value
Age, per additional decade 2.07 1.26, 3.41 0.004
Disease duration, per year 1.01 0.95, 1.07 0.823
College educated 0.47 0.18, 1.26 0.134
Oxygen therapy 2.08 0.93, 4.62 0.074
Presentation with
chest pain
0.29 0.08, 1.05 0.059Specific characteristics of the LAM patient population
may explain these differences. While some of the same
factors and reasons found in previous studies apply to the
LAM patient population, other barriers are unique and may
arise due to the small patient population that consists
mostly of women. The small size of the group allows for
a greater connection between individuals, and as a result,
a strong ‘‘group persona’’ is evident that is not usually
present with larger patient populations. This combined
with the tight friendships that LAM patients have with each
other may influence decisions made by individuals. There-
fore, certain motivating factors and barriers to clinical trial
participation may exist because of the group persona and
thus may be unique to rare diseases. We found that
subjects who were older and had their diagnosis for at least
3 years were more likely to participate in a clinical trial.
Furthermore, the association observed between age and
disease duration with altruistic motivation suggests that as
people with a rare disease become older and have more
shared experiences they become more altruistic toward the
community with the disease. This is in contrast to evalua-
tions of patients with gynecological diseases, in which older
patients are far less likely to participate in trials.5,14
Moreover, LAM patients are far more likely to cite altruistic
intent, as opposed to greater access to treatment forFigure 1 Reasons cited for the decision against participation
in a clinical trial among patients with LAM (NZ 222).
Figure 2 Reasons cited for the decision to participate in
a clinical trial among patients with LAM (NZ 41).
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to the importance of group identity. Interestingly, peer
influence was not a reason frequently cited for participa-
tion in our patients, suggesting that the impact of the group
identity is not overt, but rather reflective of a general
feeling of community and shared cause in this small,
geographically disperse yet tightly knit group.
The most common reason cited for trial non-participa-
tion was that the subject did not meet enrollment criteria.
Although stringent inclusion and exclusion criteria can lead
to a homogenous study population that is best suited to
answer the scientific question, they may create a barrier to
successful trial enrollment in studies of rare diseases,
where the pool for potential study subjects is already very
small. The study impact of an individual being excluded
from trial participation in more common diseases (e.g.
cancers) is minimal as there typically are hundreds of
alternative potential participants available. In the MILES
trial, for example, study recruitment has been limited by
potential participants failing to meet predefined FEV1
criterion (<70% predicted) and the requirement for defini-
tive diagnosis, which in more than half of cases requires
tissue biopsy. Relaxing such requirements might allow for
greater enrollment, but could have potential negative
consequences. For example, without the preset FEV1
criterion, a study might have a reduced capacity to detect
an improvement in lung function, and without requiring
definitive diagnosis of LAM, patients with a disease
mimicking LAM could be exposed to undue risk. Creative
solutions to reconcile these different vantage points are
necessary for successful trials to be effectively conducted
in rare diseases.
Perhaps as interesting as the identified predictors and
reasons for clinical trial participation were those factors
that were not cited by our population. Studies in patients
with cancer and cardiovascular disease identify mistrust of
experimental methods and randomization as major barriers
to trial participation.1,15 Risk of taking placebo or off-label
medication use are often identified as threats to trialrecruitment when there is a placebo control arm or
commercially available therapeutic with a different FDA
indication. Our data suggests that these are not major
barriers to trial enrollment in this rare disease; although it
is conceivable that people who are taking drugs off label
may be less likely to respond to questionnaires. Further-
more, it appears that economic factors, geographic loca-
tion and time burdens play a limited, if any, role in the
decision to participate in a clinical trial in subjects with this
disease. Similarly, inadequate knowledge about available
trials or lack of advanced education does not appear to be
an important determinant of trial participation. These
findings should inform future targeted interventions to
improve enrollment in rare diseases.
There are several potential limitations of this study that
warrant discussion. First, the person who responds to
surveys is most likely someone who approves of medical
research and is invested in the pursuit of scientific knowl-
edge. Thus, persons who do not enroll in clinical trials
because they dislike or distrust the process (or purpose) of
the clinical trials may have been selectively excluded. We
attempted to address this limitation by including patients’
perspectives from those who had and had not participated
in clinical research in the focus group based generation of
the survey instrument. Second, survey sampling method-
ology can greatly impact the representativeness of a refer-
ence population. We attempted to mitigate this potential
weakness by partnering with a patient advocacy organiza-
tion with a mature population-based registry16,17 and
offering subjects multiple survey mediums, including paper
and electronic forms. In addition, although we tried to be
as inclusive as possible of both living and deceased patient
experiences, we had a very poor response rate amongst
family members of deceased patients. While the survey
design was carefully designed and pretested, researcher
bias still may exist. For example, in the question ‘‘Why did
you choose not to participate in a clinical trial,’’ the
choices offered represent the researchers’ hypotheses for
the reasons. Even though an ‘‘other’’ choice with a fill-in-
the-blank was available, the subject might feel more
compelled to simply check a pre-existing box. During the
process of survey design, we attempted to model the survey
in a patient relevant manner and to minimize the influence
of any pre-existing biases of the research team.
We conducted a study of barriers, motivating factors and
predictors of clinical trial participation among individuals
with a rare lung disease. Our findings indicate that the
motivation for and against clinical trial participation among
those with rare diseases may be different from those with
more common diseases like heart disease or cancer.
Specifically, altruism is a dominant motivating factor, while
older LAM patients and those with more advanced disease
and greater impact on lifestyle are more likely to have
participated in clinical trials. The impact of stringent study
entry criteria, drug toxicity and stability of disease are
important obstacles to successful trial enrollment, and may
play a more significant role in clinical trials of rare diseases
than of common ones. Future research should investigate
barriers, motivating factors, and predictors of clinical trial
participation in other rare diseases and determine effective
recruitment methods for achieving successful clinical trial
enrollment.
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